Stock Track | MannKind Soars 6.49% After Hours on $500 Million Financing Deal with Blackstone

Stock Track

Aug 07, 2025

MannKind Corporation (MNKD) saw its stock surge 6.49% in after-hours trading on Wednesday, following the announcement of a significant financing agreement with funds managed by Blackstone (BX). This development overshadowed the company's second-quarter earnings report released earlier in the day.

The strategic financing agreement, valued at up to $500 million, includes an initial term loan of $75 million to be funded at closing. The facility also provides for a $125 million delayed draw term loan available for up to 24 months, and an additional $300 million uncommitted delayed draw term loan subject to mutual consent. Set to mature in August 2030, the facility bears interest at the secured overnight financing rate plus 4.75%.

This substantial financing deal is expected to significantly bolster MannKind's financial position, potentially accelerating the company's growth initiatives and pipeline development. The biopharmaceutical firm, known for its inhaled insulin product Afrezza and other pulmonary therapeutics, could use these funds to expand its product portfolio, enhance its manufacturing capabilities, or pursue strategic acquisitions. While the company's Q2 revenue grew by 6% to $76.5 million, slightly missing analyst estimates, investors seem more focused on the long-term potential unlocked by this new financing arrangement with Blackstone.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1143434516"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143434516\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143434516?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 07:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143434516","market":"sg","top_or_hot":-1,"title":"Stock Track | MannKind Soars 6.49% After Hours on $500 Million Financing Deal with Blackstone","media":"Stock Track","content":"<p>MannKind Corporation (MNKD) saw its stock surge 6.49% in after-hours trading on Wednesday, following the announcement of a significant financing agreement with funds managed by Blackstone (BX). This development overshadowed the company's second-quarter earnings report released earlier in the day.</p>\n\n<p>The strategic financing agreement, valued at up to $500 million, includes an initial term loan of $75 million to be funded at closing. The facility also provides for a $125 million delayed draw term loan available for up to 24 months, and an additional $300 million uncommitted delayed draw term loan subject to mutual consent. Set to mature in August 2030, the facility bears interest at the secured overnight financing rate plus 4.75%.</p>\n\n<p>This substantial financing deal is expected to significantly bolster MannKind's financial position, potentially accelerating the company's growth initiatives and pipeline development. The biopharmaceutical firm, known for its inhaled insulin product Afrezza and other pulmonary therapeutics, could use these funds to expand its product portfolio, enhance its manufacturing capabilities, or pursue strategic acquisitions. While the company's Q2 revenue grew by 6% to $76.5 million, slightly missing analyst estimates, investors seem more focused on the long-term potential unlocked by this new financing arrangement with Blackstone.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MannKind Soars 6.49% After Hours on $500 Million Financing Deal with Blackstone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MannKind Soars 6.49% After Hours on $500 Million Financing Deal with Blackstone\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-07 07:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MannKind Corporation (MNKD) saw its stock surge 6.49% in after-hours trading on Wednesday, following the announcement of a significant financing agreement with funds managed by Blackstone (BX). This development overshadowed the company's second-quarter earnings report released earlier in the day.</p>\n\n<p>The strategic financing agreement, valued at up to $500 million, includes an initial term loan of $75 million to be funded at closing. The facility also provides for a $125 million delayed draw term loan available for up to 24 months, and an additional $300 million uncommitted delayed draw term loan subject to mutual consent. Set to mature in August 2030, the facility bears interest at the secured overnight financing rate plus 4.75%.</p>\n\n<p>This substantial financing deal is expected to significantly bolster MannKind's financial position, potentially accelerating the company's growth initiatives and pipeline development. The biopharmaceutical firm, known for its inhaled insulin product Afrezza and other pulmonary therapeutics, could use these funds to expand its product portfolio, enhance its manufacturing capabilities, or pursue strategic acquisitions. While the company's Q2 revenue grew by 6% to $76.5 million, slightly missing analyst estimates, investors seem more focused on the long-term potential unlocked by this new financing arrangement with Blackstone.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNKD","symbol_name":"曼恩凯德生物医疗","start_time":0,"source_url":"","article_id":"1143434516","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143434516","pubTimestamp":1754523045,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MannKind Corporation (MNKD) saw its stock surge 6.49% in after-hours trading on Wednesday, following the announcement of a significant financing agreement with funds managed by Blackstone (BX). This...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNKD":"曼恩凯德生物医疗"},"translate_title":"个股追踪|与黑石达成5亿美元融资协议MannKind盘后大涨6.49%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":1},"content_text":"MannKind Corporation (MNKD) saw its stock surge 6.49% in after-hours trading on Wednesday, following the announcement of a significant financing agreement with funds managed by Blackstone (BX). This development overshadowed the company's second-quarter earnings report released earlier in the day.\nThe strategic financing agreement, valued at up to $500 million, includes an initial term loan of $75 million to be funded at closing. The facility also provides for a $125 million delayed draw term loan available for up to 24 months, and an additional $300 million uncommitted delayed draw term loan subject to mutual consent. Set to mature in August 2030, the facility bears interest at the secured overnight financing rate plus 4.75%.\nThis substantial financing deal is expected to significantly bolster MannKind's financial position, potentially accelerating the company's growth initiatives and pipeline development. The biopharmaceutical firm, known for its inhaled insulin product Afrezza and other pulmonary therapeutics, could use these funds to expand its product portfolio, enhance its manufacturing capabilities, or pursue strategic acquisitions. While the company's Q2 revenue grew by 6% to $76.5 million, slightly missing analyst estimates, investors seem more focused on the long-term potential unlocked by this new financing arrangement with Blackstone.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}